Search This Blog

Tuesday, June 16, 2026

Adaptive Biotechnologies to separate MRD, Immune Medicine businesses, explore strategic alternatives

 

Adaptive Biotechnologies to separate MRD and Immune Medicine businesses, exploring strategic alternatives for Immune Medicine unit

  • Company evaluating strategic and structural alternatives for Immune Medicine business, targeting preferred path decision by year-end 2026
  • Adaptive Biotechnologies announces proposed $250M private offering of convertible senior notes due 2031
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)